Clinical Trial Update: Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

View source ↗

Summary

An individual patient expanded access IND for Selexipag (Uptravi) in participants with non-healing wounds due to Thromboangiitis Obliterans has been approved fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboangiitis Obliterans

Drugs mentioned

• Uptravi (selexipag)

Snippet

Sponsor: Actelion | Conditions: Non-healing Wound, Thromboangiitis Obliterans | Status: APPROVED_FOR_MARKETING